FM101 Safety, Tolerability, Efficacy Study in the Patients With Open-Angle Glaucoma or Ocular Hypertension
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
A PHASE 1/2A, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY ASSESSING THE
SAFETY, TOLERABILITY, AND EFFICACY OF FM101 IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR
HYPERTENSION, AND TO ASSESS THE RELATIVE BIOAVAILABILITY OF THE FM101 ORAL TABLET FORMULATION
IN HEALTHY PARTICIPANTS